Comparison of the effect of Fumaria Parviflora and Gabapentin in Treatment of Uremic Pruritus in Hemodialysis Patients: A Randomized Clinical Trial Study

Pruritus is a common problem in people with chronic kidney disease undergoing hemodialysis. Itching can greatly affect the quality of life. There is no widely used and agreed-upon treatment for pruritus associated with end-stage renal disease (ESRD). Fumaria parviflora L is a medicinal plant with several medicinal properties, including outstanding anti-inflammatory activity. The aim of this study was to compare the Effect of Fumaria Parviflora and Gabapentin in the Treatment of Uremic Pruritus in Hemodialysis Patients.

A total of 52 hemodialysis patients with pruritus were randomly divided into two groups receiving Fumaria Parviflora or gabapentin. One group was given 1500 mg of Fumaria Parviflora once a day for two months and the second group was given gabapentin 300 mg three times a week after dialysis for two months. Patients' pruritus scores were assessed before and after the intervention in two groups.

This study showed that pruritus in the two groups before the intervention was not significantly different. Both gabapentin and Fumaria Parviflora significantly reduced pruritus in hemodialysis patients after the intervention. There was no significant difference between the two groups in the severity of pruritus after the intervention.

The results of this study showed that both gabapentin and Fumaria Parviflora significantly reduced the rate of pruritus in hemodialysis patients. The results of this study showed that Fumaria Parviflora as a safe herbal medicine was as effective as gabapentin in reducing pruritus in uremic patients.